Neurent Medical Raises €62.5m to Expand Neuromark Rollout

Neurent Medical has secured €62.5m ($74m) in Series C funding to accelerate commercialization of Neuromark, its radiofrequency device for chronic rhinitis. The company previously received clearance from the US Food and Drug Administration for the latest version of the technology.

Neuromark delivers low-power radiofrequency energy to create targeted lesions in nasal nerves. By interrupting parasympathetic nerve signals, the treatment aims to ease symptoms such as congestion, runny nose, sneezing and itching. In a two-year study, patients experienced a 55% average reduction in Total Nasal Symptom Score, alongside improvements in postnasal drip, cough and overall quality of life.

Reimbursement momentum has supported adoption, with expanded coverage following updated payer policies in 2025.

The financing round was led by MVM Partners, with participation from Sofinnova Partners and existing investors, backing broader access to a therapy targeting a condition affecting millions of adults.

16-02-2026